When the news came through that a baby had been shot in west Bend, the community's largest town, a sense of shock and anger swept over the town.The news that a little boy had been killed while playing with a toy gun sparked an outpouring of grief and anger.But it wasn't just the news of the death that made people angry.It was the way in which the news was presented, said West Bend resident, who wi...
CCRDF President Tom Sjostrom announced the agency’s approval of the company’s second and third drug therapies for the chronic wasting disease, Chronic Traumatic Encephalopathy (CTE).
The approval is a result of a review of the drugs’ clinical trial data, a decision made by the agency last year after CCRDP submitted additional evidence of effectiveness.
CCRDEP is in the process of evaluating CTE treatment, but the drug is being considered by the FDA as a second-line therapy for patients with severe CTE.
According to a news release from the agency, the CCRDC has been studying CTE for over a decade and has been conducting an extensive, peer-reviewed, independent evaluation of all available treatment options for CTE, including two Phase II clinical trials of CTE therapy in the United States.
“We are very confident that the CCAF and the FDA will approve CCAf in a timely manner,” Sjöstrom said in a statement.
Sjostram noted the CCD drug trial data and its efficacy in terms of reducing the number of patients with the disease. “
The FDA is committed to providing quality and affordable care to patients with CTE,” he added.
Sjostram noted the CCD drug trial data and its efficacy in terms of reducing the number of patients with the disease.
The company’s therapies were developed through the NIH-funded CCRDT program, which is funded by the National Institutes of Health and is overseen by the Centers for Disease Control and Prevention.CDRDF is the largest nonprofit research institute in the world, with more than 300,000 members, with over 10,000 scientists and researchers dedicated to CTE research.